Compare Dyne Therapeutics Inc. Common Stock (DYN) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs WD 40 Company — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while WD 40 Company trades at $203.62 (market cap $2.74B). The key difference: Dyne Therapeutics Inc. Common Stock and WD 40 Company are close in size by market cap, and WD 40 Company pays a 2% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and WD 40 Company for 23 Days on average.
| DYN | WDFC | |
|---|---|---|
Market Cap | $2.86B | $2.74B |
Volume | 3,341,579 | 121,880 |
Sector | Health | Basic Materials |
52-Week High | $26.78 | $264.91 |
52-Week Low | $14.60 | $187.52 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $2.18B | $2.80B |
Dividend Yield | — | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
WDFC trades at $204.41, up 0.8% today, with a bullish technical signal from moving averages and key resistance at $206. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.33, and maintains robust profitability with a 33.22% ROE. Recent news highlights strategic growth initiatives and institutional buying interest.
Outlook is mixed; solid fundamentals and growth strategy support upside, but high valuation (P/E 31.07) and margin pressures from input costs pose risks. Analyst consensus is cautious with 71% hold ratings, indicating tempered expectations despite operational strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
